USKRC’s Artificial Kidney Research Published in Prominent Science Journal

Communications Materials, one of the Nature family of journals, has published a scientific article entitled: Simulating nephron ion transport function using activated wafer electrodeionization by Dr. I. Kurtz and colleagues. The newly published article describes US Kidney Research Corporation’s new multiple mesh electrodeionization technology that simulates kidney nephron function.

Nature is one of the world’s preeminent general science periodicals with several sister journals that deals with a great range of scientific subjects including those of medical and biomedical pertinence.

The article illuminates how electrodeionization technology can be coupled to pressure driven ultrafiltration, nanofiltration and reverse osmosis modules to create an artificial wearable or implantable kidney for patients with end-stage renal disease.

Current clinical approaches to treat patients with end-stage renal disease (ESRD) include hemodialysis, peritoneal dialysis, and renal transplantation. US Kidney Research Corporation (USKRC) has been working on a new technology that has the potential to mimic the filtration and the ion/water transport processes of kidney. The technology USKRC has developed can be potentially utilized in various configurations that include a standalone machine, peritoneal dialysis (to purify the dialysate), wearable and implantable artificial kidney devices to treat patients with compromised kidney function.

The results described in the article represent a significant advance in the field of renal replacement therapy ever since dialysis was first developed as a therapeutic modality over 70 years ago. USKRC has recently initiated animal testing of their current wearable artificial kidney device. Within approximately 2 years, with adequate funding, the company believes it will complete the proof of concept phase of animal testing in preparation for the FDA and clinical trials.

US Kidney Research Corporation (USKRC): US Kidney Research Corporation (formerly Curion Research Corporation), is a Delaware C-Corp founded in June, 2015. For over 4 years, US Kidney Research Corporation has been involved in R&D of the world’s first waterless renal replacement technology. Unlike standard dialysis, their new technology does not require purified water, dialysate concentrate solutions, or a dialyzer.

They are the first in the world to create synthetic urine (urine produced synthetically from an artificial device) during animal studies using their new blood purifying technology that involves filtration and ion transport processes similar to the native kidney.

USKRC was an award winner of KidneyX Redesign Dialysis contest sponsored in partnership by US Dept. of Health and Human Services and the American Society of Nephrology.

Website: uskidneyresearchcorp.com

About US Kidney Research Corporation

US Kidney Research Corporation (USKRC) is a Delaware C-Corp founded in June, 2015. USKRC is a leader in the field of artificial kidney research and involved in R&D of the world’s first waterless renal replacement technology.

Contrary to dialysis, their new technology does not require purified water, dialysate concentrate solutions, or a dialyzer, providing significant advantages for both the patient and provider. Their novel waterless blood purification technology is leading to the creation of a truly artificial kidney to replace dialysis and native kidney transplantation. Additionally, the same technology is being used to develop a portable wearable artificial kidney, a portable tabletop device, and ultimately an implantable artificial kidney.

USKRC is currently finishing their portable prototypes. The company says that with adequate funding their backpack and tabletop portable prototypes can be completed and ready for clinical trials within 2 to 2 1/2- years.

The company’s future plans include advancing their technology, miniaturizing their prototype for use in an implantable artificial kidney. The company is also advancing their new non-clotting filtering technology, PD dialysate regeneration, and studying the role of middle molecules (uremic toxins) including a method to detect, identify, and isolate them.

USKRC is working with Dr. Ira Kurtz, their Science/Medical Advisor/Board Member, whom also is the Chief of Nephrology at the University of California Los Angeles (UCLA) and with researchers from the Department of Chemical Engineering at the University of Arkansas, headed by Dr. Jamie Hestekin.

Website: uskidneyresearchcorp.com